These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 8093363)
41. Prodrugs of 2',3'-didehydro-3'-deoxythymidine (D4T): synthesis, antiviral activity, and rapid pharmacokinetic evaluation. Tortolani DR; Russell JW; Whiterock VJ; Hitchcock MJ; Ghazzouli I; Martin JC; Mansuri MM; Starrett JE J Pharm Sci; 1994 Mar; 83(3):339-43. PubMed ID: 8207678 [TBL] [Abstract][Full Text] [Related]
42. [Prospects in the treatment of AIDS. II. AZT and related compounds; practical conclusions]. Grieb P Pol Arch Med Wewn; 1992; 87(4-5):316-23. PubMed ID: 1381825 [No Abstract] [Full Text] [Related]
43. Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine. Crocchiolo PR; Lizioli A; Arcidiacono I; Cantaluppi P; Filippi C; Sobatti D; Bedarida G; D'Agostino F; Cambie G; Nardella ML Boll Ist Sieroter Milan; 1990 Jun; 69(2):423-30. PubMed ID: 1983798 [TBL] [Abstract][Full Text] [Related]
44. Preliminary evidence for inhibitory effect of glycyrrhizin on HIV replication in patients with AIDS. Hattori T; Ikematsu S; Koito A; Matsushita S; Maeda Y; Hada M; Fujimaki M; Takatsuki K Antiviral Res; 1989; 11(5-6):255-61. PubMed ID: 2572198 [TBL] [Abstract][Full Text] [Related]
45. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. Richman DD; Fischl MA; Grieco MH; Gottlieb MS; Volberding PA; Laskin OL; Leedom JM; Groopman JE; Mildvan D; Hirsch MS N Engl J Med; 1987 Jul; 317(4):192-7. PubMed ID: 3299090 [TBL] [Abstract][Full Text] [Related]
46. Radioimmunoassay for quantitation of 2',3'-didehydro-3'-deoxythymidine (D4T) in human plasma. Zhou XJ; Chakboub H; Ferrua B; Moravek J; Guedj R; Sommadossi JP Antimicrob Agents Chemother; 1996 Jun; 40(6):1472-5. PubMed ID: 8726021 [TBL] [Abstract][Full Text] [Related]
47. Disposition in animals of a new anti-HIV agent: 2',3'-didehydro-3'-deoxythymidine. Russell JW; Whiterock VJ; Marrero D; Klunk LJ Drug Metab Dispos; 1990; 18(2):153-7. PubMed ID: 1971565 [TBL] [Abstract][Full Text] [Related]
48. Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection: a pilot study. Arends S; van Halteren E; Kamp W; Schokker J Pharm World Sci; 1996 Jan; 18(1):30-4. PubMed ID: 8861829 [TBL] [Abstract][Full Text] [Related]
50. Safety, activity, and pharmacokinetics of GLQ223 in patients with AIDS and AIDS-related complex. Kahn JO; Gorelick KJ; Gatti G; Arri CJ; Lifson JD; Gambertoglio JG; Bostrom A; Williams R Antimicrob Agents Chemother; 1994 Feb; 38(2):260-7. PubMed ID: 7910722 [TBL] [Abstract][Full Text] [Related]
51. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Chaisson RE; Moore RD; Richman DD; Keruly J; Creagh T Am Rev Respir Dis; 1992 Aug; 146(2):285-9. PubMed ID: 1362634 [TBL] [Abstract][Full Text] [Related]
52. The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study. Stambuk D; Youle M; Hawkins D; Farthing C; Shanson D; Farmer R; Lawrence A; Gazzard B Q J Med; 1989 Feb; 70(262):161-74. PubMed ID: 2512592 [TBL] [Abstract][Full Text] [Related]
53. Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients. Rozencweig M; McLaren C; Beltangady M; Ritter J; Canetta R; Schacter L; Kelley S; Nicaise C; Smaldone L; Dunkle L Rev Infect Dis; 1990; 12 Suppl 5():S570-5. PubMed ID: 2166965 [TBL] [Abstract][Full Text] [Related]
54. Metabolism and DNA interaction of 2',3'-didehydro-2',3'-dideoxythymidine in human bone marrow cells. Zhu Z; Hitchcock MJ; Sommadossi JP Mol Pharmacol; 1991 Nov; 40(5):838-45. PubMed ID: 1658614 [TBL] [Abstract][Full Text] [Related]
55. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. Petersen EA; RamÃrez-Ronda CH; Hardy WD; Schwartz R; Sacks HS; Follansbee S; Peterson DM; Cross A; Anderson RE; Dunkle LM J Infect Dis; 1995 Mar; 171 Suppl 2():S131-9. PubMed ID: 7861018 [TBL] [Abstract][Full Text] [Related]
56. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Kline MW; Dunkle LM; Church JA; Goldsmith JC; Harris AT; Federici ME; Schultze ME; Woods L; Loewen DF; Kaul S Pediatrics; 1995 Aug; 96(2 Pt 1):247-52. PubMed ID: 7630678 [TBL] [Abstract][Full Text] [Related]
57. Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Abrams DI; Kuno S; Wong R; Jeffords K; Nash M; Molaghan JB; Gorter R; Ueno R Ann Intern Med; 1989 Feb; 110(3):183-8. PubMed ID: 2463780 [TBL] [Abstract][Full Text] [Related]